A Single-Dose Study to Assess the Penetration of Stavudine Into Human Cerebrospinal Fluid in Adults
- 1 March 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 17 (3) , 235-238
- https://doi.org/10.1097/00042560-199803010-00008
Abstract
Penetration of stavudine into the cerebrospinal fluid (CSF) was studied in healthy humans. In this open, randomized study, a single oral dose of 40 mg of stavudine was given to 12 fasting volunteers ≥ 18 years of age. Subjects were divided into three groups based on the time of CSF sampling (i.e., 0.75-1.25, 2-3, or 4-5 hours after dosing). Blood samples were collected over an 8-hour period after dosing and included a sample simultaneous with CSF collection to permit an estimate of CSF: plasma ratios. Stavudine concentrations in plasma and CSF were determined by a validated high-performance liquid chromatography method. Repeated measurements of vital signs, physical examination, and clinical laboratory tests indicated that the stavudine dose was well tolerated. CSF levels were not detected 0.75 to 1.25 hours after dosing. Thereafter, levels were detected in the CSF of five subjects; the mean concentration was 61 ng/ml. The mean CSF : plasma ratio increased with time, from 0.16 at 2 to 3 hours postdose in one subject to 0.40 at 4 to 5 hours postdose in four subjects. In conclusion, the mean stavudine concentration of 61 ng/ml achieved in the CSF of five subjects exceeds the ED50 of clinical isolates of HIV (230 nM, 52 ng/ml).Keywords
This publication has 10 references indexed in Scilit:
- Quantifying HIV-1 RNA Using the Polymerase Chain Reaction on Cerebrospinal Fluid and Serum of Seropositive Individuals With and Without Neurologic AbnormalitiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 1995
- Genotypic And Phenotypic Analysis Of Human Immunodeficiency Virus Type 1 Isolates From Patients On Prolonged Stavudine TherapyThe Journal of Infectious Diseases, 1994
- Temporal trends in the incidence of HTV‐1‐related neurologic diseasesNeurology, 1994
- Cerebrospinal fluid human immunodeficiency virus type 1 (HIV‐1) p24 antigen levels in HIV‐1–related dementiaAnnals of Neurology, 1994
- Cerebrospinal fluid p24 antigen levels and intrathecal immunoglobulin G synthesis are associated with cognitive disease severity in HIV-1AIDS, 1994
- Pharmacokinetics of Stavudine in Patients with AIDS or AIDS-Related ComplexThe Journal of Infectious Diseases, 1992
- High-performance liquid chromatographic determination of 2′,3′-didehydro-3′-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- The Brain in AIDS: Central Nervous System HIV-1 Infection and AIDS Dementia ComplexScience, 1988
- Management of Pharmacokinetic Data Using HP-3357/Mainframe Ibm InterfacingDrug Information Journal, 1987
- The application of statistical moment theory to the evaluation ofin vivo dissolution time and absorption timeJournal of Pharmacokinetics and Biopharmaceutics, 1980